Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 27 points (0.2%) at 17,393 as of Tuesday, Nov. 4, 2014, 3:25 PM ET. The NYSE advances/declines ratio sits at 1,085 issues advancing vs. 1,951 declining with 143 unchanged.

The Health Services industry as a whole was unchanged today versus the S&P 500, which was down 0.3%. Top gainers within the Health Services industry included IMRIS ( IMRS), up 6.2%, Huttig Building Products ( HBP), up 2.6%, Hooper Holmes ( HH), up 2.2%, Response Genetics ( RGDX), up 2.6% and Akers Biosciences ( AKER), up 5.1%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Response Genetics ( RGDX) is one of the companies that pushed the Health Services industry higher today. Response Genetics was up $0.02 (2.6%) to $0.77 on light volume. Throughout the day, 36,298 shares of Response Genetics exchanged hands as compared to its average daily volume of 91,900 shares. The stock ranged in a price between $0.72-$0.80 after having opened the day at $0.75 as compared to the previous trading day's close of $0.75.

Response Genetics, Inc., a life science company, is engaged in the research, development, marketing, and sale of pharmacogenomic tests for use in the treatment of cancer primarily in the United States, Asia, and Europe. Response Genetics has a market cap of $29.6 million and is part of the health care sector. Shares are down 34.1% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate Response Genetics a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Response Genetics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on RGDX go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Life Sciences Tools & Services industry. The net income has significantly decreased by 142.0% when compared to the same quarter one year ago, falling from -$1.30 million to -$3.14 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, RESPONSE GENETICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to -$3.18 million or 63.03% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 65.69%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 100.00% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • RESPONSE GENETICS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, RESPONSE GENETICS INC continued to lose money by earning -$0.24 versus -$0.31 in the prior year.

You can view the full analysis from the report here: Response Genetics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Hooper Holmes ( HH) was up $0.01 (2.2%) to $0.60 on light volume. Throughout the day, 37,134 shares of Hooper Holmes exchanged hands as compared to its average daily volume of 114,700 shares. The stock ranged in a price between $0.58-$0.60 after having opened the day at $0.59 as compared to the previous trading day's close of $0.59.

Hooper Holmes, Inc., together with its subsidiaries, provides health risk assessment services to the life insurance and health industries in the United States. The company operates through three segments: Health and Wellness, Heritage Labs, and Hooper Holmes Services. Hooper Holmes has a market cap of $39.0 million and is part of the health care sector. Shares are up 10.7% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate Hooper Holmes a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Hooper Holmes as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on HH go as follows:

  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Providers & Services industry and the overall market, HOOPER HOLMES INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • HH has underperformed the S&P 500 Index, declining 6.78% from its price level of one year ago. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • HOOPER HOLMES INC has improved earnings per share by 40.0% in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, HOOPER HOLMES INC reported poor results of -$0.17 versus -$0.11 in the prior year.
  • 36.56% is the gross profit margin for HOOPER HOLMES INC which we consider to be strong. Regardless of HH's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, HH's net profit margin of -42.11% significantly underperformed when compared to the industry average.
  • Net operating cash flow has significantly increased by 138.55% to $0.56 million when compared to the same quarter last year. In addition, HOOPER HOLMES INC has also vastly surpassed the industry average cash flow growth rate of -26.60%.

You can view the full analysis from the report here: Hooper Holmes Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

IMRIS ( IMRS) was another company that pushed the Health Services industry higher today. IMRIS was up $0.02 (6.2%) to $0.33 on average volume. Throughout the day, 125,117 shares of IMRIS exchanged hands as compared to its average daily volume of 113,700 shares. The stock ranged in a price between $0.31-$0.35 after having opened the day at $0.31 as compared to the previous trading day's close of $0.31.

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions that enable surgeons to obtain information and make decisions during the course of procedures. IMRIS has a market cap of $16.6 million and is part of the health care sector. Shares are down 79.9% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates IMRIS a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates IMRIS as a sell. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk, disappointing return on equity and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on IMRS go as follows:

  • The debt-to-equity ratio of 1.12 is relatively high when compared with the industry average, suggesting a need for better debt level management. Along with the unfavorable debt-to-equity ratio, IMRS maintains a poor quick ratio of 0.96, which illustrates the inability to avoid short-term cash problems.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, IMRIS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • IMRS's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 75.33%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • IMRIS INC has improved earnings per share by 12.5% in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, IMRIS INC reported poor results of -$0.83 versus -$0.60 in the prior year.
  • IMRS, with its very weak revenue results, has greatly underperformed against the industry average of 3.7%. Since the same quarter one year prior, revenues plummeted by 58.4%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.

You can view the full analysis from the report here: IMRIS Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.